Advertisement
UK markets closed

  • FTSE 100

    8,139.83
    +60.97 (+0.75%)
     

  • FTSE 250

    19,824.16
    +222.18 (+1.13%)
     

  • AIM

    755.28
    +2.16 (+0.29%)
     

  • GBP/EUR

    1.1679
    +0.0022 (+0.19%)
     

  • GBP/USD

    1.2491
    -0.0020 (-0.16%)
     

  • Bitcoin GBP

    51,233.88
    -709.38 (-1.37%)
     

  • CMC Crypto 200

    1,383.71
    -12.82 (-0.92%)
     

  • S&P 500

    5,099.96
    +51.54 (+1.02%)
     

  • DOW

    38,239.66
    +153.86 (+0.40%)
     

  • CRUDE OIL

    83.66
    +0.09 (+0.11%)
     

  • GOLD FUTURES

    2,349.60
    +7.10 (+0.30%)
     

  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     

  • HANG SENG

    17,651.15
    +366.61 (+2.12%)
     

  • DAX

    18,161.01
    +243.73 (+1.36%)
     

  • CAC 40

    8,088.24
    +71.59 (+0.89%)
     
PROPERTY:

9 luxury homes to consider if money is no object

Ever thought about what a multimillion pound budget would buy you?

Is AstraZeneca (AZN) Stock Outpacing Its Medical Peers This Year?

Zacks Equity Research
·2-min read

Investors focused on the Medical space have likely heard of AstraZeneca (AZN), but is the stock performing well in comparison to the rest of its sector peers? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.

AstraZeneca is a member of the Medical sector. This group includes 904 individual stocks and currently holds a Zacks Sector Rank of #5. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.

The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. AZN is currently sporting a Zacks Rank of #2 (Buy).

The Zacks Consensus Estimate for AZN's full-year earnings has moved 0.90% higher within the past quarter. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.

ADVERTISEMENT

Based on the most recent data, AZN has returned 7.82% so far this year. At the same time, Medical stocks have gained an average of 0.48%. This means that AstraZeneca is performing better than its sector in terms of year-to-date returns.

Looking more specifically, AZN belongs to the Large Cap Pharmaceuticals industry, which includes 15 individual stocks and currently sits at #22 in the Zacks Industry Rank. On average, this group has lost an average of 0.46% so far this year, meaning that AZN is performing better in terms of year-to-date returns.

Investors with an interest in Medical stocks should continue to track AZN. The stock will be looking to continue its solid performance.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
AstraZeneca PLC (AZN) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.